Breaking Finance News

BidaskClub upgraded Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to Buy in a report released today.

BidaskClub has upgraded Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to Buy in a report released on Wednesday June 21, 2017.

Yesterday Eagle Pharmaceuticals Inc (NASDAQ:EGRX) traded -0.93% lower at $80.78. The company’s 50-day moving average is $54.06 and its 200-day moving average is $73.89. The last closing price is up -19.07% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 237,365 shares of the stock traded hands, down from an average trading volume of 400,550

See Chart Below

Eagle Pharmaceuticals Inc (NASDAQ:EGRX)

Eagle Pharmaceuticals Inc has a 52 week low of $45.05 and a 52 week high of $97.15 with a P/E ratio of 10.04 The company’s market cap is currently $0.

In addition to BidaskClub reporting its stock price target, a total of 4 brokers have issued a research note on the company. The average stock price target is $81.00 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Eagle Pharmaceuticals Inc (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.